UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International

Mueller, Roman-Ulrich; Messchendorp, A Lianne; Birn, Henrik; Capasso, Giovambattista; Cornec-Le Gall, Emilie; Devuyst, Olivier; van Eerde, Albertien; ... Gansevoort, Ron T; + view all (2021) An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International. Nephrology Dialysis Transplantation 10.1093/ndt/gfab312. (In press). Green open access

[thumbnail of gfab312.pdf]
Preview
Text
gfab312.pdf - Published Version

Download (967kB) | Preview

Abstract

The approval of the vasopressin V2-receptor antagonist tolvaptan - based on the landmark TEMPO 3:4 trial - has marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). This development has advanced patient care in ADPKD from general measures to prevent progression of chronic kidney disease to targeting disease specific mechanisms. However, considering the long-term nature of this treatment as well as potential side effects, evidence-based approaches to initiate treatment only in patients with rapidly progressing disease are crucial. In 2016, the position statement issued by the ERA was the first society-based recommendation on the use of tolvaptan and has served as a widely-used decision-making tool for nephrologists. Since then, considerable practical experience regarding the use of tolvaptan in ADPKD has accumulated. More importantly, additional data from REPRISE, a second randomized clinical trial (RCT) examining the use of tolvaptan in later stage disease has added important evidence to the field, as have post-hoc studies of these RCTs. To incorporate this new knowledge, we provide an updated algorithm to guide patient selection for treatment with tolvaptan and add practical advice for its use.

Type: Article
Title: An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International
Location: England
Open access status: An open access version is available from UCL Discovery
DOI: 10.1093/ndt/gfab312
Publisher version: https://doi.org/10.1093/ndt/gfab312
Language: English
Additional information: © The Author(s) 2021. Published by Oxford University Press on behalf of the ERA. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Keywords: Science & Technology, Life Sciences & Biomedicine, Transplantation, Urology & Nephrology, ADPKD, polycystic kidney disease, position statement, tolvaptan, vasopressin V2 receptor antagonist, PROGRESSION, ANTAGONIST, BIOMARKERS, MANAGEMENT, VESICLES, EQUATION, TRIALS, SALT
UCL classification: UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Renal Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
URI: https://discovery.ucl.ac.uk/id/eprint/10146102
Downloads since deposit
8Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item